K279-1469 Screening compound: 2-[(3-{2-[(1,3-BENZODIOXOL-5-YLMETHYL)AMINO]-2-OXOETHYL}-2-OXO-2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLIN-5-YL)SULFANYL]-N~1~-(3,4-DIMETHOXYPHENETHYL)ACETAMIDE

K279-1469 Screening compound: 2-[(3-{2-[(1,3-BENZODIOXOL-5-YLMETHYL)AMINO]-2-OXOETHYL}-2-OXO-2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLIN-5-YL)SULFANYL]-N~1~-(3,4-DIMETHOXYPHENETHYL)ACETAMIDE
K279-1469 Screening compound: 2-[(3-{2-[(1,3-BENZODIOXOL-5-YLMETHYL)AMINO]-2-OXOETHYL}-2-OXO-2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLIN-5-YL)SULFANYL]-N~1~-(3,4-DIMETHOXYPHENETHYL)ACETAMIDE alternative view

Chemical Structure Depiction of ChemDiv screening compound K279-1469
2-[(3-{2-[(1,3-BENZODIOXOL-5-YLMETHYL)AMINO]-2-OXOETHYL}-2-OXO-2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLIN-5-YL)SULFANYL]-N~1~-(3,4-DIMETHOXYPHENETHYL)ACETAMIDE

Available from 1 mg

Formats:

  • Glass Vials (4ml Glass Vials VWR #97047-678)
  • 96-tube racks (Matrix #4247 96-well 1.4ml sealed with capmats, empty cols 1 & 12, 100uL of 10mM)

Shiptime: 1 week worldwide delivery in most cases

Compound Identifiers

ChemDiv Compound ID

K279-1469

Molecular Formula

C32H31N5O7S (C32 H31 N5 O7 S)

Compound Name

2-[(3-{2-[(1,3-BENZODIOXOL-5-YLMETHYL)AMINO]-2-OXOETHYL}-2-OXO-2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLIN-5-YL)SULFANYL]-N~1~-(3,4-DIMETHOXYPHENETHYL)ACETAMIDE

IUPAC name

n/a

SMILES

COc(ccc(CCNC(CSC(N1C2CC(NCc(cc3)cc4c3OCO4)=O)=Nc(cccc3)c3C1=NC2=O)=O)c1)c1OC

InChI

InChI=1S/C32H31N5O7S/c1-41-24-9-7-19(13-26(24)42-2)11-12-33-29(39)17-45-32-35-22-6-4-3-5-21(22)30-36-31(40)23(37(30)32)15-28(38)34-16-20-8-10-25-27(14-20)44-18-43-25/h3-10,13-14,23H,11-12,15-18H2,1-2H3,(H,33,39)(H,34,38)/t23-/m0/s1

InChI Key

DFEAPRVRIJAUMK-QHCPKHFHSA-N

MDL Number (MFCD)

Chemical and Physical Properties

Saltdata

n/a

Molecular Weight

629.69

Hydrogen Bond Acceptors Count

13.00

Hydrogen Bond Donors Count

2.00

Rotatable Bond Count

14.00

Number of Nitrogen and Oxygen Atoms

12

Partition Coefficient, logP

1.617

Distribution Coefficient, logD

1.616

Water Solubility, LogSw

-2.73

Polar Surface Area

116.312

Acid Dissociation Constant (pKa)

11.05

Base Dissociation Constant (pKb)

4.86

Number of Chiral Centers

1.00

Percent sp3 carbon bonding

28.10

K279-1469 in Drug Discovery

Included in Screening Libraries

300k Representative Compounds Library (Bemis-Murcko Clustering Algorithm) (286253 compounds)

Eccentric PPI Library (11937 compounds)

Protein-Protein Interaction Library (218420 compounds)

Regenerative Medicine Focused Library (23016 compounds)

Protein Tyrosine Phosphatase Non-receptor Type (PTPN) Targeted Library (32556 compounds)

Included in 1.7M Stock Database

Mechanism of action:
  • PPI modulators
  • PPI modulators
Structure:
  • Cyclic compounds
Therapeutical areas:
  • Musculoskeletal
  • Digestive system
  • Hemic and lymphatic
  • Cardiovascular
  • Skin
  • wounds
  • Cancer
  • Nervous system
  • Male
  • Female
  • Hemic and lymphatic
  • Skin
  • Endocrine
Targets:
  • Phosphatases

References: we are preparing a list of scientific research reports with K279-1469 chemical compound. It will be published here after verification.

Frequently Asked Questions

How to purchase chemical compound K279-1469?
Check Price and Availability of K279-1469, then you can add required amount to the Shopping Cart. In the Shopping Cart you can again refine your selection. Once you are sure that it’s exactly what you want you can move forward with the Checkout (to pay online by credit card, or via PayPal), or Request a Quote.
What is the minimum amount of K279-1469 you sell to drug discovery company or institution?
Available from 1 mg in Glass Vials or 96-tube racks.
Delivery options for K279-1469
ChemDiv sends parcels with Express services (UPS, WC).
  • 1–2 days for small orders
  • 2–4 weeks for large selections
Delivery formats for K279-1469
  • 0.5–50 mg of dry powder sample in single glass vials, custom vials
  • DMSO solutions frozen 10μl–250μl@10mM (96 and 384 format)

Custom synthesis of K279-1469 available by request